70 related articles for article (PubMed ID: 36495317)
1. Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
Etekal T; Koehn K; Sborov DW; McClune B; Prasad V; Haslam A; Berger K; Booth C; Al Hadidi S; Abdallah AO; Goodman A; Mohyuddin GR
Br J Haematol; 2023 Mar; 200(5):587-594. PubMed ID: 36495317
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis.
Paoletti X; Lewsley LA; Daniele G; Cook A; Yanaihara N; Tinker A; Kristensen G; Ottevanger PB; Aravantinos G; Miller A; Boere IA; Fruscio R; Reyners AKL; Pujade-Lauraine E; Harkin A; Pignata S; Kagimura T; Welch S; Paul J; Karamouza E; Glasspool RM;
JAMA Netw Open; 2020 Jan; 3(1):e1918939. PubMed ID: 31922558
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.
Dimopoulos M; Sonneveld P; Manier S; Lam A; Roccia T; Schecter JM; Cost P; Pacaud L; Poirier A; Tremblay G; Lan T; Valluri S; Kumar S
BMC Cancer; 2024 Apr; 24(1):541. PubMed ID: 38684948
[TBL] [Abstract][Full Text] [Related]
4. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer.
Garside J; Shen Q; Westermayer B; van de Ven M; Kroep S; Chirikov V; Juhasz-Böss I
Clin Ther; 2023 Oct; 45(10):983-990. PubMed ID: 37689551
[TBL] [Abstract][Full Text] [Related]
5. Objective response rate and progression-free survival as surrogates for overall survival treatment effect: A meta-analysis across diverse tumour groups and contemporary therapies.
Shahnam A; Hitchen N; Nindra U; Manoharan S; Desai J; Tran B; Solomon B; Luen SJ; Hui R; Hopkins AM; Sorich MJ
Eur J Cancer; 2024 Feb; 198():113503. PubMed ID: 38134560
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of progression-free survival as a surrogate end point in primary CNS lymphoma: a systematic review and meta-analysis.
Zhan J; Yang S; Zhang W; Zhou D; Zhao D; Zhang Y; Wang W; Wei C
Future Oncol; 2023 Oct; 19(31):2123-2133. PubMed ID: 37882339
[No Abstract] [Full Text] [Related]
7. Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.
Rotolo F; Pignon JP; Bourhis J; Marguet S; Leclercq J; Tong Ng W; Ma J; Chan AT; Huang PY; Zhu G; Chua DT; Chen Y; Mai HQ; Kwong DL; Soong YL; Moon J; Tung Y; Chi KH; Fountzilas G; Zhang L; Hui EP; Lee AW; Blanchard P; Michiels S;
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 27927756
[TBL] [Abstract][Full Text] [Related]
8. Surrogacy of one-year survival for overall survival in advanced hepatocellular carcinoma.
Jin Y; Ren H; Yue Q; Wu W; Liu C; Guo Y; Zhao P
BMC Cancer; 2024 Feb; 24(1):258. PubMed ID: 38395854
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of progression-free survival as a surrogate endpoint for overall survival in locally advanced or metastatic differentiated thyroid cancer: a systematic review.
Yang S; Zhan J; Xu X
Endocrine; 2023 Dec; 82(3):491-497. PubMed ID: 37702900
[TBL] [Abstract][Full Text] [Related]
10. Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials.
Woodford R; Zhou D; Kok PS; Lord SJ; Friedlander M; Marschner I; Simes RJ; Lee CK
JCO Precis Oncol; 2024 Jan; 8():e2300296. PubMed ID: 38207226
[TBL] [Abstract][Full Text] [Related]
11. Progression-free survival is a weakly predictive surrogate end-point for overall survival in follicular lymphoma: A systematic review and meta-analysis.
Milrod CJ; Kim KW; Raker C; Ollila TA; Olszewski AJ; Pelcovits A
Br J Haematol; 2024 Apr; ():. PubMed ID: 38571449
[TBL] [Abstract][Full Text] [Related]
12. Multiple myeloma: Unveiling the survival data with different lines of treatments.
Kurian H; Abraham S; Antony A; Jiju JA; Thomas T
J Cancer Res Ther; 2023; 19(3):720-724. PubMed ID: 37470600
[TBL] [Abstract][Full Text] [Related]
13. Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Matsuda S; Itonaga I; Tsumura H
Sci Rep; 2020 May; 10(1):8573. PubMed ID: 32444660
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).
Bonnetain F; Bonsing B; Conroy T; Dousseau A; Glimelius B; Haustermans K; Lacaine F; Van Laethem JL; Aparicio T; Aust D; Bassi C; Berger V; Chamorey E; Chibaudel B; Dahan L; De Gramont A; Delpero JR; Dervenis C; Ducreux M; Gal J; Gerber E; Ghaneh P; Hammel P; Hendlisz A; Jooste V; Labianca R; Latouche A; Lutz M; Macarulla T; Malka D; Mauer M; Mitry E; Neoptolemos J; Pessaux P; Sauvanet A; Tabernero J; Taieb J; van Tienhoven G; Gourgou-Bourgade S; Bellera C; Mathoulin-Pélissier S; Collette L
Eur J Cancer; 2014 Nov; 50(17):2983-93. PubMed ID: 25256896
[TBL] [Abstract][Full Text] [Related]
15. Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis.
Shahnam A; Nindra U; Desai J; Hui R; Buyse M; Hopkins AM; Sorich MJ
J Natl Cancer Inst; 2023 Dec; 115(12):1475-1482. PubMed ID: 37540222
[TBL] [Abstract][Full Text] [Related]
16. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls.
Wright K; Mittal A; Gyawali B
Curr Opin Oncol; 2023 Nov; 35(6):513-521. PubMed ID: 37621175
[TBL] [Abstract][Full Text] [Related]
17. A multistate platform model for time-to-event endpoints in oncology clinical trials.
Lin CW; Nagase M; Doshi S; Dutta S
CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):154-167. PubMed ID: 37860956
[TBL] [Abstract][Full Text] [Related]
18. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma.
Paiva B; Zherniakova A; Nuñez-Córdoba JM; Rodriguez-Otero P; Shi Q; Munshi NC; Durie BGM; San-Miguel J
Blood Adv; 2024 Jan; 8(1):219-223. PubMed ID: 37639322
[No Abstract] [Full Text] [Related]
19. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed.
Walia A; Tuia J; Prasad V
Nat Rev Clin Oncol; 2023 Dec; 20(12):885-895. PubMed ID: 37828154
[TBL] [Abstract][Full Text] [Related]
20. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs.
Booth CM; Eisenhauer EA; Gyawali B; Tannock IF
J Clin Oncol; 2023 Nov; 41(32):4968-4972. PubMed ID: 37733981
[No Abstract] [Full Text] [Related]
[Next] [New Search]
